Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy
Department of Pediatrics; Program in Molecular Medicine; Department of Medicine, Division of Diabetes; Department of Molecular Genetics and Microbiology
AIDS Vaccines; Adolescent; *Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cytokines; Female; Flow Cytometry; Fowlpox virus; Gene Products, gag; HIV Antibodies; HIV Infections; HIV-1; Humans; Interferon-gamma; Male; Prospective Studies; RNA, Viral; T-Lymphocytes; Vaccines, Synthetic; Vaccinia; Young Adult
Immunology and Infectious Disease | Pediatrics
A trial to evaluate the safety and immunogenicity of recombinant modified vaccinia Ankara (MVA) and fowlpox (FP) vectors expressing multiple HIV-1 proteins was conducted in twenty HIV-1 infected youth with suppressed viral replication on HAART. The MVA and FP-based multigene HIV-1 vaccines were safe and well tolerated. Increased frequencies of HIV-1 specific CD4+ proliferative responses and cytokine secreting cells were detected following immunization. Increased frequencies and breadth of HIV-1 specific CD8 T-cell responses were also detected. Plasma HIV-1-specific antibody levels and neutralizing activity were unchanged following vaccination. Poxvirus-based vaccines may merit further study in therapeutic vaccine protocols.
DOI of Published Version
Vaccine. 2008 Dec 9;26(52):6883-93. Epub 2008 Oct 20. Link to article on publisher's site
Greenough TC, Cunningham CK, Muresan P, McManus MM, Persaud D, Fenton T, Barker P, Gaur A, Panicali D, Sullivan JL, Luzuriaga K. (2008). Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Immunology/Infectious Disease. https://doi.org/10.1016/j.vaccine.2008.09.084. Retrieved from https://escholarship.umassmed.edu/peds_immunology/57